AMRN

Amarin Corporation PLC is a Dublin-based biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases, with a primary emphasis on the U.S. market. Its flagship product, Vascepa, is a prescription medication recognized for its efficacy in significantly lowering triglyceride levels among patients with elevated cardiovascular risk. The company is committed to advancing its research pipeline, exploring new clinical applications for Vascepa, and expanding market access to strengthen its foothold within the cardiovascular health sector. With a strategic focus on innovation and patient outcomes, Amarin is poised to remain a significant contributor to advancements in cardiovascular therapeutics.